ASO-Sort1

ASO-Sort1 is an antisense oligonucleotide designed to selectively target the mRNA encoding sortilin 1 (SORT1), a transmembrane protein frequently overexpressed in various cancer types and implicated in key metabolic processes. By binding to SORT1 mRNA, ASO-Sort1 induces its degradation via RNase H-mediated mechanisms, thereby reducing SORT1 protein levels in target tissues. This targeted knockdown approach is under preclinical and early clinical investigation for its potential to modulate disease-related pathways, especially those involving tumor progression or metabolic dysfunction. The precise developer, manufacturing entity, and clinical status may not be publicly disclosed, indicating that ASO-Sort1 is likely still in the discovery or early translational research phase. The concept builds upon evidence that SORT1 inhibition, including via peptide-drug conjugates and ligand-guided delivery, is a promising approach in oncology and potentially other therapeutics domains[9][3][1].

Other names

ASO-Sort1ASO-Sort-1ASO-Sort 1